Diagnostic Biomarkers

Diagnostic Biomarkers Market Outlook

The global diagnostic biomarkers market is projected to reach approximately USD 50 billion by 2035, growing at a Compound Annual Growth Rate (CAGR) of around 9% during the forecast period of 2025 to 2035. The rising incidence of chronic diseases, advancements in proteomics and genomics technologies, and an increasing focus on personalized medicine are significant growth factors contributing to the market's expansion. Additionally, the growing demand for rapid and accurate diagnostic tools in both clinical and research settings is boosting the adoption of diagnostic biomarkers. Furthermore, the increasing investments in healthcare infrastructure and diagnostic research in emerging economies are expected to provide substantial opportunities for market growth. The ongoing scientific research and the development of innovative diagnostic solutions, including liquid biopsy and companion diagnostics, are paving the way for advanced biomarker applications in various healthcare domains.

Growth Factor of the Market

The growth of the diagnostic biomarkers market is significantly driven by the increasing prevalence of diseases such as cancer, cardiovascular disorders, and infectious diseases. As healthcare professionals increasingly adopt precision medicine approaches tailored to individual patient needs, the demand for biomarker-based diagnostics has surged. Moreover, technological advancements in biomarker discovery and validation techniques such as next-generation sequencing (NGS) and mass spectrometry have enhanced the efficiency and accuracy of these diagnostic tools, fostering market growth. Regulatory support and initiatives aimed at promoting biomarker research are also facilitating the entry of new products into the market, capturing the attention of stakeholders across the healthcare continuum. Additionally, the rise in public awareness regarding preventive healthcare and routine screening is influencing the adoption of diagnostic biomarkers among patients and healthcare providers.

Key Highlights of the Market

• The diagnostic biomarkers market is projected to reach USD 50 billion by 2035.
• Rapid advancements in genomic and proteomic technologies are driving market growth.
• Oncology application holds the largest share, fueled by rising cancer incidences.
• North America is leading the global market, owing to established healthcare infrastructure.
• Emerging markets in Asia Pacific and Latin America present significant growth opportunities.

By Type

Proteomic Biomarkers:

Proteomic biomarkers involve the study of proteins and their functions, providing critical insights into disease mechanisms and potential therapeutic targets. These biomarkers are increasingly utilized in oncology, where they help identify tumor-specific proteins that can indicate disease progression or response to treatment. The specificity and sensitivity offered by proteomic biomarkers make them highly valuable in clinical diagnostics, enabling early detection and monitoring of various diseases. Furthermore, advances in technologies such as mass spectrometry and protein microarrays have accelerated the identification of new proteomic biomarkers, promoting their application in personalized medicine.

Genomic Biomarkers:

Genomic biomarkers refer to the genetic variations that can influence individual responses to diseases and treatments. These biomarkers are particularly crucial in the field of oncology for identifying patients who are likely to benefit from specific targeted therapies. The integration of genomic biomarkers in clinical practice has enhanced the precision of oncology treatments, as they allow for tailored therapeutic strategies based on a patient's unique genetic makeup. The rise of next-generation sequencing technologies has also facilitated the rapid discovery and validation of genomic biomarkers, contributing to their growing acceptance in diagnostics and personalized medicine.

Metabolomic Biomarkers:

Metabolomic biomarkers involve the comprehensive analysis of metabolic profiles within biological systems, providing valuable insights into disease processes. These biomarkers are gaining traction in various applications, including oncology and cardiovascular disease monitoring, as they can reveal metabolic dysregulations indicative of disease states. The ability to analyze metabolites rapidly through advanced techniques such as gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS) has enhanced the utility of metabolomic biomarkers in clinical settings. Their role in understanding complex biochemical pathways further supports their application in drug discovery and disease management.

Immunologic Biomarkers:

Immunologic biomarkers are crucial for understanding immune responses related to various diseases, including autoimmune disorders and cancers. These biomarkers facilitate the monitoring of immune status and therapeutic responses in patients, offering critical information for disease management. The growing emphasis on immunotherapy in oncology underscores the importance of immunologic biomarkers in predicting patient responses and outcomes. As research in immunology continues to evolve, the development of novel immunologic biomarkers will likely enhance the capability to tailor treatments and improve patient prognoses.

Neurological Biomarkers:

Neurological biomarkers are instrumental in diagnosing and monitoring neurological disorders, including Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease. As research delves deeper into the pathophysiology of these conditions, the identification of suitable neurological biomarkers has become increasingly essential. Advances in imaging techniques and cerebrospinal fluid analysis have enabled the discovery of biomarkers that can reveal disease progression and therapeutic efficacy. The demand for accurate and reliable neurological diagnostics is expected to drive significant growth in this segment, establishing neurological biomarkers as an integral component of modern clinical practice.

By Application

Oncology:

Oncology is the leading application segment for diagnostic biomarkers, driven by the escalating incidence of cancer worldwide. The integration of biomarkers in cancer diagnostics has revolutionized the approach to disease identification, treatment selection, and patient monitoring. In particular, biomarkers enable oncologists to classify tumors, predict treatment responses, and assess disease progression, thereby enhancing patient outcomes. Furthermore, the development of companion diagnostics, which pair specific biomarkers with targeted therapies, is reshaping the landscape of cancer treatment. The continuous advancements in biomarker research and technology are anticipated to further bolster the oncology segment in the coming years.

Infectious Diseases:

Diagnostic biomarkers for infectious diseases play a vital role in the early identification and management of various pathogens, including bacteria, viruses, and fungi. The increased prevalence of infectious diseases globally, along with the rising concerns surrounding antibiotic resistance, emphasizes the need for rapid and accurate diagnostic tools. Biomarkers can assist in distinguishing between viral and bacterial infections, guiding appropriate treatment decisions. Additionally, the ongoing research efforts and technological innovations in biomarker discovery are expected to expand their applications in the diagnosis and monitoring of emerging infectious diseases, ensuring timely healthcare interventions.

Cardiovascular Diseases:

The application of diagnostic biomarkers in cardiovascular diseases is gaining momentum, primarily due to the growing burden of heart-related ailments worldwide. Biomarkers such as troponins and natriuretic peptides have become critical components in diagnosing and managing conditions like myocardial infarction and heart failure. The ability to assess cardiac biomarkers provides healthcare professionals with valuable information regarding patient prognosis and treatment efficacy. As research continues to uncover new cardiovascular biomarkers, the application of diagnostics in this area is set to advance, ultimately improving patient care and health outcomes.

Neurological Disorders:

Diagnostic biomarkers for neurological disorders are increasingly recognized for their potential to facilitate the early diagnosis and monitoring of conditions such as Alzheimer’s disease and epilepsy. The complexity of neurological diseases often makes diagnosis challenging; however, biomarkers can help identify specific pathological changes in the brain, leading to more accurate diagnoses. Moreover, ongoing studies are focusing on the development of biomarkers that can predict disease progression and responses to treatment, providing essential insights into patient management. As the understanding of neurology expands, the integration of diagnostic biomarkers in clinical practice is expected to enhance patient care significantly.

Others:

The "Others" segment encompasses a variety of applications where diagnostic biomarkers are employed beyond the primary disease categories. This includes applications in metabolic disorders, autoimmune diseases, and various rare conditions. The diversity of biomarkers across different diseases highlights their widespread relevance in modern diagnostics. The increasing integration of biomarkers into routine clinical practice for various health conditions signifies the growing recognition of their potential benefits, thus broadening their application scope. As healthcare continues to evolve with a focus on precision medicine, the importance of this segment is anticipated to rise, facilitating better patient outcomes across diverse medical fields.

By User

Hospitals:

Hospitals are among the primary end-users of diagnostic biomarkers, leveraging these tools to enhance patient care through improved diagnostics and treatment monitoring. The integration of biomarkers into hospital settings allows for more accurate disease identification, facilitating timely interventions that can significantly improve patient outcomes. Furthermore, hospitals are increasingly adopting advanced diagnostic technologies, such as liquid biopsy assays and molecular diagnostics, to streamline patient management processes. The trend toward personalized medicine is creating further demand for diagnostic biomarkers, as hospitals strive to provide tailored healthcare solutions that align with each patient's unique medical profile.

Diagnostic Centers:

Diagnostic centers play a crucial role in the proliferation of diagnostic biomarkers, providing specialized testing services for a variety of diseases. These centers are equipped with advanced laboratory facilities that enable the efficient analysis of biomarker assays, catering to both healthcare providers and patients seeking accurate diagnostic information. As the need for rapid and precise diagnostic testing increases, diagnostic centers are adapting their services to include a broader range of biomarker tests, enhancing their market position. The collaboration between diagnostic centers and hospitals, as well as research institutions, fosters innovation and advances in biomarker development, ultimately benefiting the healthcare ecosystem.

Research Institutes:

Research institutes are at the forefront of biomarker discovery and validation, conducting critical studies that pave the way for new diagnostic applications. These institutions are heavily involved in the exploration of biological markers across various disease states, thereby contributing significantly to the advancement of medical knowledge. By collaborating with pharmaceutical companies and healthcare providers, research institutes facilitate the transition of novel biomarkers from laboratory settings to clinical practice. The ongoing investment in research and development within these institutions is expected to yield new insights and innovative diagnostic solutions, further propelling the growth of the diagnostic biomarkers market.

Others:

The "Others" category encompasses various users of diagnostic biomarkers, including pharmaceutical companies, academic institutions, and governmental health agencies. These stakeholders utilize biomarkers to support drug development processes, conduct epidemiological studies, and evaluate public health interventions. The engagement of these diverse users in biomarker research and application underscores the importance of diagnostic biomarkers in a wide array of healthcare contexts. As the demand for innovative diagnostic solutions continues to rise, the involvement of various end-users will be pivotal in driving advancements in the diagnostic biomarkers market.

By Disease Type

Cancer:

Cancer represents a significant portion of the diagnostic biomarkers market due to the increasing prevalence of malignancies globally. Biomarkers in cancer diagnostics are essential for identifying tumor types, predicting treatment responses, and monitoring disease progression. The development of targeted therapies and immunotherapies has further underscored the need for effective biomarker applications within oncology. As research unfolds, the identification of novel cancer biomarkers through liquid biopsies and next-generation sequencing technologies is predicted to enhance early diagnosis and improve treatment outcomes for cancer patients.

Infectious Diseases:

Infectious diseases constitute a critical segment of the diagnostic biomarkers market, especially in light of the recent global health crises. The rapid identification of pathogens using biomarkers is crucial for effective disease management and containment. The ability to differentiate between types of infections and determine specific treatment regimens based on biomarker profiles is enhancing patient outcomes. Continued investment in research and technological advancements is expected to expand the utility of infectious disease biomarkers, thus solidifying their importance in clinical diagnostics.

Cardiovascular Disorders:

Cardiovascular disorders are among the leading causes of morbidity and mortality worldwide, making the development of diagnostic biomarkers in this field indispensable. Biomarkers such as high-sensitivity troponin and B-type natriuretic peptide (BNP) are frequently employed to assess cardiac function and predict patient outcomes. The ongoing research into novel cardiovascular biomarkers aims to improve early detection and management of heart diseases, thereby enhancing the quality of care. With the rising prevalence of lifestyle-related cardiovascular conditions, the demand for effective biomarker-based diagnostics is set to grow significantly.

Neurological Disorders:

Neurological disorders encompass a diverse range of conditions that often present diagnostic challenges due to their complex nature. Diagnostic biomarkers play a pivotal role in accurately diagnosing diseases such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. As research enhances our understanding of the underlying mechanisms of these disorders, the development of reliable biomarkers for early detection and monitoring will be vital. The integration of biomarkers into clinical practice will improve the management of neurological conditions and potentially lead to the discovery of novel therapeutic targets.

Others:

The "Others" segment includes a variety of diseases where diagnostic biomarkers are utilized, such as metabolic disorders, autoimmune diseases, and rare genetic conditions. This diverse range of applications highlights the widespread relevance and importance of biomarkers in modern healthcare. The continuous advancements in biomarker research and the demand for personalized medicine will likely drive the development of innovative diagnostic solutions across various disease categories. As the healthcare industry evolves, the role of diagnostic biomarkers in detecting and managing diverse medical conditions will become increasingly critical.

By Region

The diagnostic biomarkers market is expected to witness substantial regional growth, with North America leading the charge, accounting for approximately 40% of the global market share in 2025. The region's dominance is attributed to its advanced healthcare infrastructure, high levels of investment in research and development, and the presence of key market players focused on biomarker discovery and application. Moreover, supportive regulatory environments and increased awareness among healthcare professionals regarding the benefits of diagnostic biomarkers further bolster market growth in North America. The CAGR for North America is expected to reach around 10% over the forecast period, reflecting the region's commitment to advancing biomarker research.

In Europe, the diagnostic biomarkers market is projected to maintain a significant share, driven by the increasing prevalence of chronic diseases and a growing demand for innovative diagnostic solutions. The European region is characterized by active collaborations between academic institutions and the biotech industry, fostering advancements in biomarker discovery. Countries such as Germany, the UK, and France are at the forefront of biomarker research, significantly contributing to market growth in the region. Meanwhile, the Asia Pacific region is anticipated to experience the fastest growth rate, fueled by rising investments in healthcare infrastructure, increased awareness of preventive healthcare, and the implementation of advanced diagnostic technologies across emerging economies.

Opportunities

The diagnostic biomarkers market presents a wealth of opportunities driven by the ongoing advancements in technology and increasing focus on personalized medicine. The integration of artificial intelligence and machine learning in biomarker research is expected to expedite the identification and validation processes, ultimately leading to the discovery of new biomarkers for various diseases. Additionally, the growing number of collaborations between pharmaceutical companies and research institutions underscores the potential for innovation in biomarker applications, particularly in drug development and companion diagnostics. Furthermore, the rise in awareness regarding preventive healthcare and the importance of early disease detection will likely propel the demand for diagnostic biomarkers, creating numerous growth opportunities for market players.

Emerging markets, particularly in the Asia Pacific region, offer significant growth potential for the diagnostic biomarkers market. As healthcare systems in these regions develop and modernize, the demand for advanced diagnostic solutions will increase. Investments in healthcare infrastructure, research initiatives, and regulatory support for biomarker development will play a crucial role in driving market expansion. Moreover, the increasing prevalence of chronic diseases in these regions necessitates the implementation of effective diagnostic tools, further enhancing the opportunities for stakeholders in the diagnostic biomarkers market.

Threats

Despite the promising growth of the diagnostic biomarkers market, several threats could hinder its progress. One of the primary concerns is the rising costs associated with biomarker research and development, which may limit access to advanced diagnostic solutions, particularly in low-resource settings. Additionally, the complex nature of biomarker validation and regulatory challenges could impede the timely introduction of new products into the market. The potential for misinterpretation of biomarker results due to variability in testing methods or laboratory standards poses another threat, which could undermine the reliability of diagnostic tools. Furthermore, the rapid pace of technological advancements may lead to market saturation, resulting in intensified competition among players and the risk of product obsolescence.

Another significant threat to the diagnostic biomarkers market is the potential for ethical and privacy concerns related to genetic testing and data usage. As the market increasingly relies on genomic and proteomic information, ensuring the protection of patient data and addressing ethical considerations becomes paramount. Regulatory bodies must establish comprehensive guidelines to govern the use of biomarkers in clinical practice, balancing innovation with the need for patient safeguards. Failure to address these concerns could undermine public trust in biomarker diagnostics and hinder market growth.

Competitor Outlook

• Roche Diagnostics
• Abbott Laboratories
• Thermo Fisher Scientific
• Siemens Healthineers
• Bio-Rad Laboratories
• Illumina, Inc.
• Qiagen N.V.
• Agilent Technologies, Inc.
• PerkinElmer, Inc.
• Myriad Genetics, Inc.
• Exact Sciences Corporation
• HTG Molecular Diagnostics, Inc.
• Epigenomics AG
• Genomic Health, Inc.
• Merck KGaA

The competitive landscape of the diagnostic biomarkers market is characterized by a diverse range of players, including established multinational corporations and innovative startups. Key companies such as Roche Diagnostics and Abbott Laboratories are leading the market, leveraging their extensive portfolios of biomarker assays and diagnostic solutions to maintain a strong market presence. These companies invest heavily in research and development to enhance their product offerings and ensure compliance with regulatory standards. Additionally, strategic partnerships and collaborations with research institutions and healthcare providers are common among these market leaders, facilitating access to cutting-edge technologies and expanding their reach within the industry.

Moreover, the emergence of biotechnology companies dedicated to biomarker discovery is reshaping the competitive landscape. For instance, Illumina, Inc. is revolutionizing the field of genomics and diagnostics with its advanced sequencing technologies, while companies like Myriad Genetics focus on developing targeted genomic tests for cancer. These innovative players are continually striving to introduce novel biomarkers to market, thereby driving competition and fostering advancements in diagnostic capabilities. The rise of companion diagnostics and personalized medicine is further intensifying competition as companies aim to develop integrated solutions that cater to individual patient needs.

Additionally, regional players in the diagnostic biomarkers market are also making significant strides, particularly in emerging economies where healthcare demand is rapidly growing. Companies within these regions are increasingly focused on developing affordable and accessible diagnostic solutions to cater to specific local needs. As the global market evolves, it is expected that both established players and emerging companies will continue to innovate and adapt, ensuring the sustained growth of the diagnostic biomarkers market. The competitive dynamics will be influenced by ongoing advancements in technology, regulatory changes, and shifts in healthcare paradigms aimed at enhancing patient outcomes.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Merck KGaA
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Qiagen N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Epigenomics AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Illumina, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 PerkinElmer, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Roche Diagnostics
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Abbott Laboratories
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Bio-Rad Laboratories
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Genomic Health, Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Siemens Healthineers
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Myriad Genetics, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Thermo Fisher Scientific
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Agilent Technologies, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Exact Sciences Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 HTG Molecular Diagnostics, Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Diagnostic Biomarkers Market, By Type
    • 6.1.1 Proteomic Biomarkers
    • 6.1.2 Genomic Biomarkers
    • 6.1.3 Metabolomic Biomarkers
    • 6.1.4 Immunologic Biomarkers
    • 6.1.5 Neurological Biomarkers
  • 6.2 Diagnostic Biomarkers Market, By User
    • 6.2.1 Hospitals
    • 6.2.2 Diagnostic Centers
    • 6.2.3 Research Institutes
    • 6.2.4 Others
  • 6.3 Diagnostic Biomarkers Market, By Application
    • 6.3.1 Oncology
    • 6.3.2 Infectious Diseases
    • 6.3.3 Cardiovascular Diseases
    • 6.3.4 Neurological Disorders
    • 6.3.5 Others
  • 6.4 Diagnostic Biomarkers Market, By Disease Type
    • 6.4.1 Cancer
    • 6.4.2 Infectious Diseases
    • 6.4.3 Cardiovascular Disorders
    • 6.4.4 Neurological Disorders
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Diagnostic Biomarkers Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Diagnostic Biomarkers market is categorized based on

By Type

• Proteomic Biomarkers
• Genomic Biomarkers
• Metabolomic Biomarkers
• Immunologic Biomarkers
• Neurological Biomarkers

By Application

• Oncology
• Infectious Diseases
• Cardiovascular Diseases
• Neurological Disorders
• Others

By User

• Hospitals
• Diagnostic Centers
• Research Institutes
• Others

By Disease Type

• Cancer
• Infectious Diseases
• Cardiovascular Disorders
• Neurological Disorders
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Roche Diagnostics
• Abbott Laboratories
• Thermo Fisher Scientific
• Siemens Healthineers
• Bio-Rad Laboratories
• Illumina, Inc.
• Qiagen N.V.
• Agilent Technologies, Inc.
• PerkinElmer, Inc.
• Myriad Genetics, Inc.
• Exact Sciences Corporation
• HTG Molecular Diagnostics, Inc.
• Epigenomics AG
• Genomic Health, Inc.
• Merck KGaA